Related Experiment Video
Updated: Mar 14, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis
Caroline W H de Fijter1, Lily Jakulj2, Fariba Amiri2
1Internal Medicine/Nephrology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands c.w.h.defijter@olvg.nl.
Abstract:
With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis.Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.
Insights
Daily intraperitoneal meropenem (125 mg/L) effectively treats peritoneal dialysis-related peritonitis caused by multidrug-resistant bacteria. Serial drug measurements confirmed safe dosing over 21 days.
Area of Science:
- Pharmacology
- Infectious Diseases
- Nephrology
Background:
- Rising prevalence of multidrug-resistant gram-negative bacteria necessitates effective antibiotic strategies.
- Carbapenems are increasingly utilized, yet pharmacokinetic data for meropenem in peritoneal dialysis (PD)-related peritonitis is limited.
Observation:
- This study investigated the pharmacokinetics of repeated intraperitoneal (IP) meropenem administration over 21 days.
- Treatment targeted polymicrobial, multidrug-resistant PD-related peritonitis.
Findings:
- A daily dose of 125 mg/L intraperitoneal meropenem administered in all PD fluid bags proved effective and safe.
- Serial drug concentration measurements up to 21 days indicated no instances of over- or underdosing.
Implications:
- Supports the use of 125 mg/L IP meropenem as a standard treatment for PD-associated peritonitis.
- Provides crucial pharmacokinetic data for optimizing meropenem dosing in PD patients with resistant infections.
- Highlights a safe and effective therapeutic option for a challenging clinical scenario.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis I: Introduction and Procedure
Acute Pyelonephritis II: Diagnostic Studies and Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Acute Pyelonephritis I: Introduction

